Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Approval of Unaudited Standalone and Consolidated Financial Results
Date of Board Meeting / Approval: July 29, 2026
Audit Opinion: Unqualified (Limited Review Report)
Auditor’s Comment: The statutory auditor issued an unqualified limited review report. Nothing has come to their attention that causes them to believe the statement contains any material misstatement.
Key Financial Highlights [All figures in ₹ million]
Standalone Results:
Revenue from Operations: ₹6,630 (Q1 FY27) vs ₹7,993 (Q1 FY26) - Decrease of 17.0% YoY
Total Income: ₹6,878 (Q1 FY27) vs ₹8,159 (Q1 FY26)
Net Profit: Loss of ₹(21) (Q1 FY27) vs Profit of ₹740 (Q1 FY26)
EPS: (₹0.05) basic and diluted (not annualised) vs ₹1.84 basic (Q1 FY26)
Other Equity: Not Specified
Cash and Cash Equivalents: Not Specified
Debt: Not Specified
Consolidated Results:
Revenue from Operations: ₹7,360 (Q1 FY27) vs ₹8,745 (Q1 FY26) - Decrease of 15.8% YoY; vs ₹10,365 (Q4 FY26)
Total Income: ₹7,613 (Q1 FY27) vs ₹8,922 (Q1 FY26)
Net Profit: Loss of ₹(90) (Q1 FY27) vs Profit of ₹867 (Q1 FY26); Profit attributable to owners: Not Specified
EPS: (₹0.22) basic and diluted (not annualised) vs ₹2.16 basic (Q1 FY26)
Other Equity: ₹44,362 (as of March 31, 2026)
Cash and Cash Equivalents: Not Specified
Debt: Not Specified
Exceptional Items: Q1 FY27 consolidated exceptional loss of ₹135 million, comprising termination benefits. This follows a net exceptional expense of ₹462 million for FY26 related to labor code implementation and termination benefits.
Segment-wise Performance:
The Group operates in a single segment of providing Contract Research and Manufacturing Services. No segment-wise breakdown provided beyond consolidated numbers.
Corporate Actions:
Dividend: The Board recommended a final dividend of ₹1.25 per equity share (face value ₹10 each) for approval at the Annual General Meeting.
Share Allotment: On April 29, 2026, the Board approved allotment of 729,727 equity shares at face value to Syngene Employees Welfare Trust for implementation of the Long Term Incentive Performance Share Plan 2023.
Other Significant Information:
Capitalization: During Q1 FY27, ₹293 million in pre-operating costs were capitalized under capital work in progress for the US biologics site acquisition.
Acquisition History: Reference is made to the acquisition of a biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC during Q4 FY25, with total capitalized costs of ₹2,981 million plus additional costs in FY26.
Facility License: In Q1 FY26, the company was granted licenses for a drug substance production line and bonded warehouse at its Bangalore biologics facility, leading to capitalization of ₹3,438 million and higher depreciation.
Entities in Consolidation: The consolidated results include Syngene International Limited (including its employee welfare trust), Syngene USA Inc., Syngene Scientific Solutions Limited, and Syngene Manufacturing Solutions Limited (in liquidation from June 15, 2026).